NCT05134727View on ClinicalTrials.gov

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

AZD5055

Healthy participants will receive AZD5055

DRUG

Placebo

Healthy participants will receive placebo

Trial Locations (1)

21225

Research Site, Brooklyn

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY